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Synthetic macromolecular chemotherapeutics inspired by host defence peptides can disrupt cell
membranes and are emerging as agents for the treatment of cancer and infections. However, their off-
target effects remain a major unmet challenge. Here we introduce a covalent recruitment strategy,
whereby metabolic oligosaccharide engineering is used to label targeted cells with azido glycans, to
subsequently capture chemotherapeutic polymers by a bio-orthogonal click reaction. This results in up
to 10-fold reduction in EC50 and widening of the therapeutic window. Cell death is induced by not only
membrane leakage, but also by apoptosis due to the conjugated chemotherapeutic being internalised by
glycan recycling. Covalent recruitment also lead to increased penetration and significant cell death in
a 3-D tumour model in just 3 hours, whereas doxorubicin required 24 hours. This conceptual approach
of ‘engineering cells to capture polymers’ rather than ‘engineering polymers to target cells’ will bring
new opportunities in non-traditional macromolecular therapeutics.Introduction
Chemotherapeutic cancer treatments, although widely used,
have many outstanding issues limiting their therapeutic
performance. Cancer cells oen possess intrinsic drug resis-
tance and can develop multidrug resistance (MDR) which is
largely believed to be a stable and heritable process.1 This has
led to the development of several distinct classes of chemo-
therapeutics including alkylating agents,2 anti-metabolites,3
topoisomerase inhibitors4 and mitotic inhibitors.5,6 In addition
to aggressive resistance development, low aqueous solubility,
insufficient drug accumulation, off-target toxicity and rapid
clearance remain major drawbacks.7 Advancements in drug
delivery carrier systems may in the future mitigate some of
these issues but the development of drug resistance mecha-
nisms and cellular barriers still remain a concern.8 Drugwick, Coventry, CV4 7AL, UK. E-mail: m.i.
wick, Coventry, CV4 7AL, UK
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the Royal Society of Chemistrydelivery systems are also limited by burst release, off-target
toxicity, limited efficacy of the enhanced permeation and
retention (EPR) effect and endogenous target-receptor
saturation.9,10
Synthetic macromolecular therapeutic agents that mimic
host defence peptides (HDPs) and antimicrobial peptides
(AMPs) have been widely explored as potent antimicrobial
agents.11–13 These amphiphilic, cationic therapeutic agents
disrupt bacterial cell surfaces through electrostatic interactions
with anionic membrane components and have improved
pharmacokinetic properties compared to their natural coun-
terparts.14 Synthetic and natural HDPs also possess tumour-
icidal properties by selectively disrupting cancer cell
membranes due to the presence of excess anionic constituents
including phosphatidylserine, sialic acid, and heparin
sulphate.15–18 However, for both antimicrobial and anticancer
applications, selectivity for diseased cells, verses healthy, is
a key obstacle;19 the polymers must kill the cancer cells at
concentrations far below that of killing healthy cells. Current
strategies to improve cationic polymer therapeutic function
have focused on altering structural complexity (e.g. copolymers
with hydrophobic/philic groups) in search of a ‘sweet spot’
where anti-tumoural activity exceeds intrinsic cell toxicity.16,20–22
Micelles generated from biodegradable triblock copolymers of
PEG, guanidinium-functionalised polycarbonate (PGC) and
polylactide (PLL), and also cationic diblock polycarbonates,
possess activity against multiple cancerous cell lines.20,22
Treatment of 4T1 mouse breast tumour-bearing mice with
cationic PGC polymers (20 mg kg1) lead to a 3-fold reduction
in tumour volume in vivo.22 However, it is crucial to note thatChem. Sci.
























































































View Article Onlinethese HDP/AMP mimics only induce necrosis unlike their
natural counterparts which trigger additional (non-lytic)
apoptotic mechanisms to ensure that resistance development
is unlikely and provide broad-spectrum activity.17 In addition,
the reliance of non-specic electrostatic and hydrophobic
interactions as targeting mechanisms limits selectivity, so there
is a clear need to explore alternative methods to deliver
polymer-based chemotherapeutics to cells.
The above cancer targeting methods focus on the ‘magic
bullet’ (Ehrlich) approach, where the carrier is tuned to locate
the disease through targeting groups, physicochemical tuning
or by following metabolic gradients.23,24 As selectivity remains
the major issue, we therefore considered the opposite, that
cancerous cells themselves can be tuned for bio-orthogonal
covalent recruitment of synthetic chemotherapeutic macro-
molecules by introducing cell surface unnatural target recep-
tors.25 Metabolic oligosaccharide engineering (MOE) enables
the selective introduction of bio-orthogonal reactive ‘handles’
onto cell surfaces in vitro and in vivo by hijacking the promis-
cuous glycan biosynthetic pathways of endogenous sugars,
which we have previously used to ‘capture’ abiotic polymeric
materials with the correct reactive handle (e.g. azide/alkyne).26–28
Nanoparticle delivery to tumour-bearing mice has been
accomplished in vivo utilising MOE for the delivery of imaging
agents,29 chemotherapeutic drugs30 and photodynamicFig. 1 Polymer synthesis and concept. (A) A two-step approach to devel
relying on initial installation of azido glycans onto the cell surface usin
synthesis of DBCO-modified pDMAEMAn with SEC characterisation in
troscopy. ‡ Theoretical molecular weight (Mn,th) was calculated based on
determined by SEC analysis.
Chem. Sci.therapy.31 In addition, Park et al. devised a glycan precursor
which is activated by intra-tumoural hydrogen peroxide for the
recruitment of antibodies and a photosensitizer (Zn-
tetraphenylporphyrin) to induce natural killer cell and reactive
oxygen species-mediated cell death, respectively.32 Therefore,
we hypothesised that tumour cells modied with unnatural
glycans would enable the covalent capture of suitably modied
cationic AMP/HDP mimetic polymers to enhance the concen-
tration localised at the cancer cell surface whilst minimising
treatment dosage to reduce off-target toxicity and increase
selectivity. Furthermore, by targeting glycans, the cationic
polymers can possibly enter the cell during glycan recycling to
access themitochondria, golgi apparatus and nucleus which are
knownmechanisms to induce apoptosis, in addition to necrosis
from membrane damage, an advantage to current AMP/HDP
mimics.33,34
Herein, we report an alternative to the current approach of
iteratively ‘engineering chemotherapeutic polymers to target
cells’ and instead show that ‘engineering cells to capture poly-
mers’ leads to gains in efficacy and selectivity. This is achieved
using metabolic oligosaccharide engineering of tumour cells to
introduce azides into their glycocalyx, which selectively captures
chemotherapeutic polymers by copper-free click reactions.
Comparable or superior EC values were achieved compared to
structurally complex AMP mimics and small moleculeop a selective macromolecular chemotherapeutic system was devised
g MOE followed by treatment with a DBCO-modified polycation; (B)
the table. † Monomer conversion was determined by 1H NMR spec-
monomer conversion. §Molecular weight (Mn,exp) and dispersity (Đ) was
© 2021 The Author(s). Published by the Royal Society of Chemistry
























































































View Article Onlinechemotherapeutics. The covalent capture of chemotherapeutic
polymers was also shown to induce additional apoptotic path-
ways compared to non-covalent strategies and enhanced activity
was demonstrated in a 3-D tumour model.Results and discussion
Synthesis of macromolecular chemotherapeutic
Poly[2-(dimethylamino)ethyl methacrylate] (pDMAEMA) was
selected as a model polycation, due to its well-established
cytotoxicity/membrane lytic prole,35–37 to probe if covalent
recruitment onto azido labelled cells can enhance its low-to-
moderate cytotoxic properties, Fig. 1A. Well-dened, dibenzo-
cyclooctyne (DBCO) terminated cationic pDMAEMA polymers
(DBCO-pDMAEMAn, 4–6) were synthesised via reversible addi-
tion–fragmentation chain-transfer (RAFT) polymerisation of
DMAEMA with a pentauorophenyl 2-(dodecylth-
iocarbonothioylthio)-2-methylpropionic acid (PFP-DMP) RAFT
agent (PFP-pDMAEMAn, 1–3), followed by displacement of the
PFP with DBCO-NH2, Fig. 1B. Polymer characterisation and
DBCO conjugation was achieved using 1H, 13C and 19F NMR, IR
and SEC (Fig. S4–S15 and Table S1–S3†), showing low dispersity
values (1.1–1.2), Fig. 1B. DBCO-pDMAEMAn was conjugated
with N-(5-uoresceinyl)maleimide (Fl) via the u-terminal thiol
to provide imaging capabilities (DBCO-DMAEMAn–Fl, 7–8),
however DBCO-pDMAEMAn polymers unlabelled with uores-
cein (4–6) were used for viability and cytotoxicity assays to
prevent colorimetric interference.Enhancing chemotherapeutic macromolecules using a two-
step MOE approach
The core hypothesis of this work is that MOE can be used to
enhance the chemotherapeutic properties of cationic polymers,
by using cell surface installed azido glycans to capture
a complementary strained alkyne cationic polymer, localise it at
the cell membrane and hence selectively enhance activity. To
explore this, three cancerous cell lines (A549, SW480 and MCF-
7) were treated with N-azidoacetylmannosamine-tetraacylated
(Ac4ManNAz) (40 mM, 96 h), to introduce azides to the glyco-
calyx, and subsequently incubated with DBCO-pDMAEMA50–150
(0–250 mg mL1) for 2.5 h. Cell viability was measured 24 h post-
treatment and compared to cells untreated with Ac4ManNAz but
still treated with DBCO-pDMAEMA50–150 (0–250 mg mL
1, 2.5 h)
using the resazurin reduction assay (Fig. 2A). In line with our
core hypothesis, the chemotherapeutic activity of DBCO-
pDMAEMAn was signicantly increased against azido glycan
labelled cells compared to unlabelled cells at equal DBCO-
pDMAEMAn and a reduction in the concentration required to
induce signicant cell death was observed; conrming
successful enhancement of DBCO-pDMAEMAn's chemothera-
peutic properties. Dose–response curves (in full in Fig. S17†)
were plotted from the resazurin data to calculate EC50 values
(effective concentration at which cell viability was reduced by
50%) for DBCO-pDMAEMA50–150 against cells treated with and
without Ac4ManNAz and have been summarised in Table 1. For
each cell and polymer combination, a drop in EC50 values was© 2021 The Author(s). Published by the Royal Society of Chemistryobserved with the incorporation of azido glycans. SW480 cells
showed the largest increase in activity (i.e. reduced EC50) of
92.6%, whereas A549 and MCF-7 cells showed slightly lower
decreases in EC50 of 71.8% and 78.6%, respectively. The varia-
tion between cell type and changes in EC50 values can be
attributed to differences in glycan composition, growth rates
and overall stability of cell type to chemical stress. DBCO-100
possessed the lowest EC50 values across all cell types, despite
previous reports suggesting that pDMAEMA molecular weight
weakly inuences cytotoxicity,35,38 whereas DBCO-50 and DBCO-
150 polymers offered higher selectivity towards azido labelled.
Indeed, through careful selection of polymer chain length and
concentrations it was possible to identify conditions where
unlabelled cells retain >90% cell viability whereas metabolically
labelled cells drop to <20% with DBCO-50 and DBCO-150
polymers, Fig. 2A. Compared to the highly potent PEG–PGCm–
PLAn triblock polymers tested by Zhong et al. on A549 cell
lines,22 DBCO-pDMAEMA50–150 achieved lower EC50 values
(average 2.5-fold lower) with the incorporation of azido glycans
on the same cell line demonstrating that covalent recruitment
of chemotherapeutic macromolecules signicant enhances
activity beyond complex macromolecular engineering.
To compare DBCO-pDMAEMAn against a conventional
chemotherapeutic, azido glycan labelled and unlabelled cells
were treated with doxorubicin (0–250 mg mL1) for 2.5 h, 24 h
and 48 h and cell viability was measured using the resazurin
assay, Fig. S18.† DBCO-pDMAEMAn was able to act rapidly, in
2.5 h, whereas doxorubicin required over 24 h incubation to
induce signicant cell death (with no effect of /+ Ac4ManNAz)
showing that covalent recruitment of polycations has a kinetic
benet compared to some small molecule chemotherapeutics.
DBCO-pDMAEMAn was able to reduce the cell viability of Ac4-
ManNAz labelled SW480 and MCF-7 cells more than doxoru-
bicin even post 24 h incubation. DBCO-pDMAEMAn (0–500 mg
mL1, 3 h) caused insignicant levels of haemolysis against
ovine blood (<3%), Fig. S19,† demonstrating the necessary
biocompatibility for in vivo translation.
Chemotherapeutic polycationic polymers have been re-
ported to induce cell death via induction of necrosis, unpro-
grammed cell death in response to overwhelming chemical or
physical stimuli, resulting in damage to the cell membrane.20,22
To probe necrotic mechanisms, the release of lactate dehydro-
genase (LDH), a cytosolic enzyme, was measured Fig. 2B. A
signicant increase in LDH release was observed through the
incorporation of an Ac4ManNAz pre-treatment compared to
unmodied cells. The LDH release curves (Fig. 2B) similarity to
the dose–response curves from the cell viability resazurin assays
(Fig. S17†) supports the hypothesis that loss of membrane
integrity is a primary cause of cell death, as expected.39,40
Interestingly, in several cases LDH release for Ac4ManNAz
untreated cells plateaued at lower levels compared to Ac4-
ManNAz treated cells, even at higher DBCO-pDMAEMAn
concentrations, supporting our hypothesis that electrostatic
interactions alone limit the effective concentration of chemo-
therapeutic macromolecules at the cell surface compared to
those subjected to MOE.Chem. Sci.
Fig. 2 Enhancing polymer cytotoxicity with MOE. (A) Cell viability was monitored by resazurin reduction (n¼ 5), (B) membrane leakage assessed
via LDH release assay (n ¼ 3) and (C) percentage live cells determined using calcein (green) and ethidium iodide (red) staining (n ¼ 4) of cells
following treatment with (+) and without () Ac4ManNAz (40 mM, 96 h) and DBCO-pDMAEMAn. Representative live/dead images are provided at
DBCO-pDMAEMAn concentrations where Ac4ManNAz significantly increased cell death. Data is represented by mean  SEM of n biological
repeats (ANOVA, Tukey PostHoc; ns: p $ 0.05, *p # 0.05, **p # 0.01, ***p # 0.001). Scale bar ¼ 200 mm.
Chem. Sci. © 2021 The Author(s). Published by the Royal Society of Chemistry

























































































Table 1 Summary EC50 values of DBCO-DMAEMAn (0–250 mg mL
1, 2.5 h) with (+) and without () Ac4ManNAz pre-treatment determined by





N3 +N3 N3 +N3 N3 +N3
DBCO-50 102.0  2.7a 15.8  0.6a >250a 9.2  0.3a 144.6  13.7a 21.1  0.7a
DBCO-100 19.3  0.9a 8.4  0.3a 100.7  10.1a 8.9  0.4a 65.8  6.2a 16.6  1.6a
39.9  2.4b 13.9  0.4b 45.2  2.2b 10.9  1.3b 12.9  0.4b 7.5  0.3b
DBCO-150 38.7  1.6a 9.8  0.3a 166.9  2.0a 10.0  0.5a 128.0  10.1a 31.1  1.0a
58.8  1.0b 19.7  1.1b 108.8  4.1b 14.7  2.2b 145.8  20.0b 37.1  2.5b
a Average EC50 value from resazurin dose–response curves  SEM of 5 biological repeats. b Average EC50 value from calcein and EI dose–response
curves  SEM of 4 biological repeats.
























































































View Article OnlineTo further probe necrosis, cells treated with or without Ac4-
ManNAz (40 mM, 96 h) and DBCO-pDMAEMA100/150 (0–250 mg
mL1, 2.5 h) were stained with calcein (green, healthy, intact
membrane) and ethidium iodide (EI, red, dead, damaged
membrane) and imaged, Fig. 2C (additional images in Fig. S21–
S22†). Dose–response curves were generated from the
percentage of live cells counted, Fig. 2C, and EC50 values were
determined, Table 1. A signicant increase in EI positive cells
was observed with an Ac4ManNAz pre-treatment at equal DBCO-
DMAEMA100/150 concentrations, especially with DBCO-150
which decreased the EC50 values by 75.8% on average across
all cell types (see Table S5† for all values). Similar to the
previous assays, through careful selection of DBCO-150
concentrations the number of EI positive cells across all cell
types can be minimised in ‘normal’ untargeted cells to achieve
an average of 80% live cells verses just 15% for Ac4ManNAz
treated cells, revealing targeted cytotoxicity towards azido
glycan labelled cells. The similarities between the EC50 values
from live/dead staining and resazurin assays, Table 1, conrm
that cell surface lysis is a major contributor to the enhancement
in cell death caused by our chemotherapeutic macromolecular
system, a feature that could be exploited for enhanced gene
transfection or delivery of small molecule chemotherapeutics (a
concept currently being investigated to enhance drug effects in
MDR cells).15
Additional mechanism of cell death enhanced by MOE
pDMAEMA has been reported to induce both necrosis and
apoptosis (programmed cell death), although this varies
between cell type.38,41 Therefore, determining if our MOE
recruitment approach promotes and/or enhances these path-
ways must be explored. To probe this, A549, SW480 and MCF-7
cells were treated with or without Ac4ManNAz (40 mM, 96 h),
incubated with DBCO-pDMAEMAn and immediately stained
with Annexin V-FITC and propidium iodide (PI), a standardised
test for apoptosis (Fig. S24–S26†). A small portion of cells were
Annexin V positive, the marker for early apoptosis (external-
isation of phosphatidylserine), whereas the vast majority of cells
were both Annexin V-FITC and PI positive, indicative of either
late apoptosis or necrotic cell death. Whilst this is a standard
test for apoptosis, there is a risk of false positive/negative results© 2021 The Author(s). Published by the Royal Society of Chemistryas PI uptake can be aided by the polycation induced membrane
damage, and hence additional tests were conducted. Poly-
cations can induce apoptosis through perturbation of the
mitochondria, resulting in release of cytochrome c (Cyt c) and
subsequent induction of executioner caspases (cysteinyl
aspartate-specic proteases), such as caspase-3/7.42,43 To inves-
tigate this, the activation of caspase-3/7 in A549 and SW480 cell
lines pre-treated with and without Ac4ManNAz was imaged in
real-time whilst incubated with DBCO-pDMAEMA100/150 poly-
mers (0–125 mg mL1, 0–4 h) (images in Fig. S27–S30†) and the
percentage of caspase positive cells was determined to conrm
the presence of apoptosis over time, Fig. 3A. Rapid caspase
activation was observed within 30 min at DBCO-pDMAEMAn
concentrations above 31.3 mg mL1 for A549 cells and 15.6 mg
mL1 for SW480 cells, regardless of polymer chain length,
which conrms the induction of apoptosis and supports the
hypothesis that DBCO-pDMAEMA100/150 damages the cell
membrane resulting in cytosolic internalisation and damage to
membrane-bound organelles such as the mitochondria and
potentially lysosomes, endoplasmic reticulum and golgi appa-
ratus.34 The percentage of caspase positive cells increased over
the 4 h polymer incubation period. Similar to the previous
assays (in Fig. 2), caspase activation was signicantly enhanced
through the incorporation of cell surface azido glycans at all
time points measured, but particularly at 2.5 h incubation
(same as previous assays) and with DBCO-150 (62.5 mgmL1, 2.5
h) where the average number of caspase positive cells (both
A549 and SW480) increased from 11% to 71%.
EC50 values calculated from the percentage of caspase posi-
tive cells following 2.5 h incubation with DBCO-pDMAEMA100/
150, Table 2, were higher than those reported for the previous
cell viability assay, Table 1. The discrepancies between EC50
values of the different assays suggest that both the induction of
necrosis, through chemical stress exerted to the cell membrane,
and apoptosis-mediated pathways contribute to cell death. In
addition, higher concentrations of DBCO-pDMAEMA100/150 may
also be required to induce apoptosis due to the requirement of
higher cytosolic concentrations compared to necrosis which
depend on extracellular concentrations. Regardless, the caspase
EC50 values of both DBCO-100 and DBCO-150 were decreased
towards Ac4ManNAz treated cells conrming that MOE can beChem. Sci.
Fig. 3 Apoptosis measurements. (A) Caspase activation of A549 and SW480 cells treated with (+) and without () Ac4ManNAz (40 mM, 96 h) and
DBCO-pDMAEMAn (0–125 mgmL
1, 0.5–4 h) was imaged in real-time and the average percentage of caspase positive cells SEM of 4 biological
repeats was determined (ANOVA, Tukey PostHoc; ns: p $ 0.05, *p # 0.05, **p # 0.01, ***p # 0.001). (B) Confocal images of A549 and SW480
cells treated with Ac4ManNAz (40 mM, 96 h) and DBCO-pDMAEMA100/150–Fl (125 mg mL
1, 2.5 h, green) were taken along with cells treated with
Ac4ManNAz (40 mM, 96 h), DBCO-pDMAEMA100/150 (125 mg mL
1, 2.5 h), a nuclear stain (NucBlue™, blue) and CellMask™membrane stain (red).
Apoptotic features including blebbing (white arrows), apoptotic bodies and cell debris (red arrows) have been identified. Scale bar ¼ 10 mm.
























































































View Article Onlineused to enhance multiple cell death pathways induced by
DBCO-pDMAEMAn polymers and potentially minimise drug
resistance development.Chem. Sci.Confocal imaging of A549 and SW480 cells treated with
Ac4ManNAz and DBCO-pDMAEMA100/150–Fl (125 mg mL
1, 2.5
h) was undertaken, Fig. 3B. Although polymer was visualised© 2021 The Author(s). Published by the Royal Society of Chemistry
Table 2 Caspase EC50 values of DBCO-DMAEMAn with (+) and
without () Ac4ManNAz pre-treatment. Average EC50 values from






N3 +N3 N3 +N3
DBCO-100 72.4  4.7 41.5  3.0 68.0  5.2 32.5  1.6
DBCO-150 160.9  10.7 54.4  4.5 134.4  4.2 34.6  2.6
























































































View Article Onlinethroughout the whole cell bodies, higher regions of uores-
cence intensity was found co-localised with undamaged cell
membrane remains and apoptosis-associated morphological
changes such as blebs, apoptotic bodies and cell debris; addi-
tional confocal images can be found in the ESI† of lower DBCO-
pDMAEMA100/150–Fl concentrations, Fig. S33 and S34.†
CellMask™ Deep Red plasma membrane staining was used to
conrm the presence of membrane damage and the previous
morphological changes. Polymer untreated cells showed highly
localised membrane staining of the peripheral membrane,
Fig. S35,† however polymer incubation resulted in extensive
membrane damage leading to intracellular dye uptake, Fig. 3B.
Thus, these ndings further conrm that DBCO-pDMAEMA100/
150 induces both necrotic and apoptotic pathways and can be
modied to produce a dual functional imaging and cytotoxic
agent which is crucial in the further development of trackable
polycationic chemotherapeutic agents.
Two-step MOE chemotherapeutic approach on spheroids
Encouraged by the above observations that covalent recruit-
ment of chemotherapeutic polycations to cell surface glycans
leads to enhanced chemotherapeutic activity, via both mem-
brolytic and non-membrolytic processes, a more complex 3-D
cellular system was explored. Cell monolayers do not suffi-
ciently recapitulate tumour microenvironments, which alters
cellular behaviours, nor the additional challenge of permeation.
A549 spheroids were formed in the presence and absence of
Ac4ManNAz (40 mM, 96 h), Fig. 4A, with an average diameter of
595  23 mm, which is within the size range capable of
mimicking various properties of human solid tumours
including hypoxic and acidic environments, which in turn
inuences cell cycle arrest, energy metabolism and the mech-
anism of small molecule chemotherapeutics that rely on oxygen
species as their dominant mechanism of cell death.44,45
Conrmation of successful labelling of spheroids with azido
glycans was achieved by confocal microscopy with a DBCO-Cy3
dye, Fig. S44.† Spheroids formed in the presence and absence of
Ac4ManNAz were subsequently treated with a single dose of
DBCO-150 (0–250 mgmL1, 3 h), stained with CellTox™ reagent,
imaged and counted, Fig. 4B and C; spheroid treatments with
DBCO-100 and lysis controls can be found in the ESI (Fig. S46–
S48†). [Images were recoloured to show dead cells as red.
Original images are in Fig. S48†]. Confocal imaging revealed
a clear increase in the number of dead cells in spheroids treated© 2021 The Author(s). Published by the Royal Society of Chemistrywith Ac4ManNAz with the use of both DBCO-100 and DBCO-150.
Spheroid cell death counts increased by an average of 1.8-fold
when MOE recruitment of DBCO-150 was used and the largest
increase (2.3-fold) was noted at the lowest concentration tested,
25 mg mL1. As expected from a single-dose treatment, the
spheroid periphery was more damaged than the interior due to
the size of the spheroid and absence of ux and additional uid
recycling mechanisms; however, this is expected to improve
with multiple polymer treatment dosages and with the addition
of in vivo circulatory networks. Conventional small molecule
chemotherapeutics are also unable to damage the entirety of
spheroids of these dimensions through single treatments,46,47
thus these ndings are highly promising and comparable to
clinically-relevant pharmaceutical compounds.
An ATP cell viability assay was employed to determine the
overall cell death of spheroids formed in Ac4ManNAz supple-
mented media or unsupplemented media and subjected to
a single dose of DBCO-100 and DBCO-150 (0–500 mg mL1, 3 h)
compared to untreated ‘healthy’ spheroids, Fig. 4D and E. A
signicant decrease in spheroid viability was observed at all
DBCO-150 concentrations by incorporating an Ac4ManNAz pre-
treatment, however high concentrations (62.5 mg mL1 or
above) were required to penetrate the core and reduce cell
viability below 55%; conrming that low concentrations of
DBCO-pDMAEMAn results in cell death localised to the spheroid
surface in the absence of ux mechanisms. Spheroids produced
with and without Ac4ManNAz were also treated with doxoru-
bicin (0–500 mg mL1) for 24 h to compare our chemothera-
peutic system against a conventional chemotherapeutic small
molecule, Fig. 4F. DBCO-100 and DBCO-150 polymers were able
to decrease the cell viability of spheroids to the same extent as
doxorubicin between 62.5 and 250 mg mL1 in far less time
(from 24 h to 3 h) once azido glycans were incorporated to the
cell surface for covalent recruitment. DBCO-pDMAEMA100/150's
ability to exploit both necrosis- and apoptosis-mediated cell
death pathways contributed to the enhanced spheroid pene-
tration depth at low incubation times and could be exploited in
combination with small molecule chemotherapeutics to aid in
increasing spheroid core delivery.20 Thus, we have demon-
strated that our two-step MOE and chemotherapeutic macro-
molecular system enhances the cytotoxic effects of polycationic
cytotoxic agents towards, not only target 2-D labelled cells but
also 3-D tumour models.
To further recapitulate a tumour and in vivo microenviron-
ment, and remove concerns over azido glycan incorporation
potentially inuencing spheroid packing due to alterations in
cell–cell contact, pre-formed spheroids (72 h) were treated with
Ac4ManNAz (40 mM, 96 h) and subjected to a single dose of
DBCO-100 and DBCO-150 (0–500 mg mL1, 3 h), Fig. 5A. Despite
the increase in spheroid size and contraction, treatment of pre-
formed spheroids with Ac4ManNAz resulted in azido glycan
incorporation throughout the spheroid, conrmed by confocal
microscopy with a DBCO-Cy3 dye, Fig. S45.† As before, an ATP
cell viability assay was used to determine overall spheroid cell
death following combinatorial treatment of Ac4ManNAz and
DBCO-100 or DBCO-150, Fig. 5B–D. In comparison to Ac4-
ManNAz untreated spheroids, a signicant increase in spheroidChem. Sci.
Fig. 4 Application of chemotherapeutic macromolecules to a 3-D tumour model azido-labelled during spheroid formation. (A) A549 spheroids
were formed in the presence (+) or absence () of Ac4ManNAz (40 mM, 96 h) and treated with single dose of DBCO-pDMAEMA150 (3 h). (B) Dead
cells were stained with CellTox™ (Red) and imaged. (C) The number of dead cells per average spheroid area (0.235mm2) was calculated from the
confocal images. Spheroid cell viability was determined by an ATP-based assay (CellTiter-Glo®) of spheroids formed in the presence (+) and
absence () of Ac4ManNAz (40 mM, 96 h) followed by either (D) DBCO-100 (3 h), (E) DBCO-150 (3 h) or (F) doxorubicin (24 h) treatment (0–500
mgmL1). The data is represented by mean SEM of 6 biological repeats (ANOVA, Tukey PostHoc; ns: p$ 0.05, *p# 0.05, **p# 0.01). Scale bar
¼ 100 mm.
























































































View Article Onlinecell death was observed using both polymers at almost all
concentrations tested. Despite the increased size of the
spheroid, the DBCO-modied polycations exhibited minimal
decrease in activity at higher concentrations,$62.5 mg mL1 for
DBCO-100 and $125 mg mL1 for DBCO-150, whereas doxoru-
bicin's performance diminished substantially compared to theChem. Sci.previous spheroids. Thus, treatment of spheroids with Ac4-
ManNAz post-formation does not appear to impede MOE
labelling capabilities and chemotherapeutic macromolecular
functionality. We anticipate multiple doses of polymer would
lead to even larger effects.© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 5 Application of chemotherapeutic macromolecules to a 3-D tumour model azido-labelled after spheroid formation. (A) A549 spheroids
were pre-formed for 72 h before treatment with (+) and () without Ac4ManNAz (40 mM, 96 h), followed by a single dose of chemotherapeutic
macromolecule. Spheroid cell viability was determined by an ATP-based assay (CellTiter-Glo®) of A549 spheroids treated with (+) and without
() Ac4ManNAz followed by either (B) DBCO-100 (3 h), (C) DBCO-150 (3 h) or (D) doxorubicin (24 h) treatment (0–500 mg mL1). The data is
represented by mean  SEM of 6 biological repeats (ANOVA, Tukey PostHoc; ns: p $ 0.05, *p # 0.05, **p # 0.01). Scale bar ¼ 100 mm.

























































































A strategy to signicantly enhance the therapeutic potential of
chemotherapeutic macromolecules has been established by
exploiting metabolic oligosaccharide engineering (MOE) of
cancerous cells, to covalently recruit chemotherapeutic poly-
mers via bio-orthogonal reactions. The covalent recruitment
strategy was designed to overcome the intrinsic cytotoxicity of
AMP/HDP polymer mimics by ensuring that, at non-toxic
concentrations, they selectively kill labelled cells by triggering
and enhancing multiple mechanisms of cell death. This is
signicant as current approaches to increase the therapeutic
window of macromolecular chemotherapeutics have focussed
on iterative tuning of polymer hydrophilicity/phobicity, rather
than chemically tuning the cellular target.
Strained alkyne-terminated poly(dimethylaminoethyl meth-
acrylate) (DBCO-pDMAEMA) was used as the prototypical
cationic macromolecular therapeutic. DBCO-pDMAEMA was
covalently recruited, by strain-promoted click, onto azido-
glycans on tumour cell surfaces, selectively introduced by
MOE using Ac4ManNAz. Against a panel of MOE treated cell
lines, DBCO-pDMAEMA's activity increased up to 10-fold (i.e.© 2021 The Author(s). Published by the Royal Society of Chemistrydecrease in EC50 value) compared to untreated cells. Conditions
were identied where >90% of unlabelled cells remained viable
whereas only <20% of labelled cells did; thus, the ‘therapeutic
window’ (i.e. selectivity) of the polycationic chemotherapeutic
was increased without changing the nature of the therapeutic
itself. Traditional macromolecular chemotherapeutics (poly-
cations) typically kill cells by necrosis caused by electrostatic
interactions/disruption of anionic membrane components. The
covalent recruitment strategy employed induced necrotic and
apoptotic mechanisms of cell death associated with organelle
damage, hypothesised to be promoted by polycation internal-
isation following membrane damage and/or via glycan recycling
pathways. Targeting multiple cell death pathways may help
avoid future resistance development.
Finally, our two-step MOE and chemotherapeutic system was
applied to 3-D spheroids models intended to more accurately
reproduce an in vivo tumour environment. Spheroids formed
from pre-labelled cells lead to signicantly enhanced cell death,
compared to untreated cells, when DBCO-pDMAEMA was
applied demonstrating the potential of this covalent capture
approach. Secondly, spheroids were initial formed in the
absence of Ac4ManNAz and then metabolically labelled to takeChem. Sci.
























































































View Article Onlineinto account any defects in spheroid packing due to cell–cell
contact alterations and assess whether spheroids can be
labelled with azido-glycans post formation, which is closer to
what might be applied in vivo. Again, enhanced cell death was
observed in MOE treated pre-formed spheroids from a single
dose of polymer. The increased size of the Ac4ManNAz treated
pre-formed spheroid did not impede polycationic activity at
higher concentrations, whereas doxorubicin's performance was
diminished. Thus, DBCO-pDMAEMA's ability to exploit both
necrosis- and apoptosis-mediated cell death pathways could be
exploited in combination with small molecule chemothera-
peutics to aid in increasing spheroid core delivery.
The universal nature of this platform may overcome the
long-standing selectivity issues associated with synthetic
chemotherapeutic macromolecules derived from host defence
peptides. Engineering the target cells to recruit chemothera-
peutic polycations, rather than just engineering of polymers,
offers a conceptually new approach to improve their efficacy and
will help advance the discovery and application of polymeric
therapeutics as active agents, rather than just as carriers.
Methods
For complete experimental methods see the ESI.†
Cell culture
Human Caucasian lung carcinoma cells (A549), human Cauca-
sian Dukes' type B colorectal adenocarcinoma cells (SW480),
and human Caucasian breast adenocarcinoma derived from
metastatic site (MCF-7) were grown in Ham's F-12K (Kaighn's)
medium (F-12K), advanced Dulbecco's Modied Eagle's
Medium (advanced DMEM) and Dulbecco's Modied Eagle's
Medium-high glucose (DMEM-high glucose), respectively, sup-
plemented with 10% fetal bovine serum (FBS) and 100 units
per mL penicillin, 100 mg mL1 streptomycin, and 250 ng mL1
amphotericin B (PSA). Cells were incubated at 37 C and 5%CO2
and passaged every 3–4 days, before reaching 70–80% con-
uency. Cells were dissociated using a balanced salt solution
containing trypsin (0.25%) and EDTA (1 mM).
General protocol for metabolic glycan labelling
A549, SW480 and MCF-7 cells were seeded in 100  20 mm TC-
treated cell culture dishes in complete cell media, as described
above, supplemented with N-azidoacetylmannosamine-
tetraacylated (Ac4ManNAz, 40 mM) in a humidied atmo-
sphere of 95% air and 5% CO2 at 37 C for 72 h. Azido modied
cells were dissociated using Accutase® solution for subsequent
experiments.
Polymer synthesis
Synthesis of PFP-50–PFP-150. 2-(Dimethylamino)ethyl
methacrylate (DMAEMA) (2.00 g, 12.7 mmol), 2-
(dodecylthiocarbonothioylthio)-2-methylpropionic acid penta-
uorophenyl ester (PFP-DMP) and 4,40-azobis(4-cyanovaleric
acid) (ACVA) were dissolved in dioxane (10 mL) at ratios pre-
sented in Table S1† to obtain 3 degrees of polymerization (DP).Chem. Sci.Mesitylene (150 mL) was used as an internal reference and an
aliquot was taken in CDCl3 for NMR analysis. The reaction
mixture was stirred under N2 for 30 min at RT and a further 16 h
at 70 C. An aliquot of the post-reaction mixture was taken for
NMR analysis in CDCl3, allowing percentage conversion calcu-
lations. The polymer was reprecipitated into hexane from THF
three times yielding a yellow polymer product, PFP-DMAEMAn
(PFP-50–PFP-150). The resulting product was dried under
vacuum and DMF SEC and 1H, 13C and 19F NMR (CDCl3) anal-
ysis was completed.
Synthesis of DBCO-50–DBCO-150. PFP-p(DMAEMA)n (0.20 g,
1 eq.), and dibenzocyclooctyne-amine (DBCO-NH2; 2 eq.) were
stirred in THF (3 mL) for 16 h. Subsequent addition of propyl
amine (1.5 eq.) for 2 h was used to ensure complete reduction of
the thiocarbonate moiety to a thiol group. The polymer was
reprecipitated into cold hexane from THF three times yielding
a white polymer product, DBCO-DMAEMAn (DBCO-50–DBCO-
150). The resulting product was dried under vacuum and
DMF SEC and 1H, 13C and 19F NMR (CDCl3) analysis was
completed.
Synthesis of FL-100 and FL-150. DBCO-p(DMAEMA)n (0.10 g,
1 eq.), and N-(5-uoresceinyl)maleimide (1.5 eq.) were dissolved
in DMF (2 mL), degassed and le to stir for 24 h. The yellow
mixture was reprecipitated into cold hexane from THF (3),
yielding a yellow uorescent polymer product. DMF SEC anal-
ysis was completed with the UV-Vis detector set at 494 nm to
demonstrate size separation and absorbance overlap. All char-
acterisation data can be found in the ESI.†
Polymer chemotherapeutic treatment and viability studies
A549 and SW480 cells, treated and untreated with Ac4ManNAz
(as described above), were seeded in a 96 well plate at a density
of 5k cells per well and MCF-7 cells at a density of 15k cells per
well, all in the presence and absence of Ac4ManNAz (40 mM) for
24 h. Following DPBS washes (3), all cells were incubated with
complete media supplemented with DBCO-p(DMAEMA)50–150
(0–250 mg mL1) for 2.5 h. Chemotherapeutic polymer solutions
were replaced with fresh complete media, following DPBS
washes (3), and cells were incubated for 24 h. Cell viability was
determined by replacing all solutions with alamarBlue® reagent
(10% v/v in cell media). Absorbance measurements were ob-
tained at 570 nm and 600 nm every 30min/1 h for 4 h tomonitor
the reduction of resazurin to resorun by viable cells. Control
cells untreated and treated with Ac4ManNAz were also treated
with alamarBlue® solution to provide a maximum resazurin
reduction value of viable cells, along with background
measurements of alamarBlue® reagent alone (10% v/v in cell
media). Percentage cell viability was reported relative to the
respective viable cell controls, either cells untreated or treated
with Ac4ManNAz. Five biological repeats were completed.
Membrane permeability and leakage assay
A549 and SW480 cells, treated and untreated with Ac4ManNAz
(as described above), were seeded in a 96 well plate at a density
of 10k cells per well and MCF-7 cells at a density of 15k cells per
well, all in the presence and absence of Ac4ManNAz (40 mM) for© 2021 The Author(s). Published by the Royal Society of Chemistry
























































































View Article Online24 h. Following DPBS washes (3), all cells were incubated with
complete media supplemented with DBCO-p(DMAEMA)100/150
(0–250 mg mL1) for 2.5 h. Lysis controls were also prepared (see
ESI†) for Ac4ManNAz treated and untreated cells to determine
maximum lactate dehydrogenase (LDH) release. The superna-
tants of polymer treated cells, the lysis controls and untreated
negative controls were transferred to a separate 96 well plate (50
mL) and LDH reaction mixture (50 mL) was added to the super-
natants (50 mL) for 30 min at RT. Stop solution (50 mL), provided
by the Thermo Scientic™ Pierce™ LDH Cytotoxicity Assay Kit,
was added and absorbance readings were recorded at 490 nm
and 680 nm to monitor active LDH release from plasma
membrane damage and as a background subtraction
measurement, respectively. Three biological repeats were
completed.
Live/dead staining
A549 and SW480 cells, treated and untreated with Ac4ManNAz
(as described above), were seeded in a 96 well plate at a density
of 10k cells per well and MCF-7 cells at a density of 15k cells per
well, all in the presence and absence of Ac4ManNAz (40 mM) for
24 h. Following DPBS washes (3), all cells were incubated with
complete media supplemented with DBCO-p(DMAEMA)50–150
(0–250 mg mL1) for 2.5 h. The polymer solutions were removed,
cells washed with DPBS (3) and incubated in complete media
for 24 h. Cells were stained with ethidium iodide (2 mM) and
calcein (2 mM) in DPBS (100 mL) for 40 min at RT. Ac4ManNAz
untreated and treated cells were also stained as control viable
cell samples and all cells were imaged using phase contrast and
blue (calcein) and green (ethidium) excitation lasers. Cells were
counted using ImageJ and values were reported as percentage
live cells relative to the total number of cells (four biological
repeats were completed).
Caspase-3/7 kinetics apoptosis assay
A549 and SW480 cells, treated and untreated with Ac4ManNAz
(as described above), were seeded in a 96 well plate at a density
of 10k cells per well, in the presence and absence of Ac4ManNAz
(40 mM) for 24 h. Following DPBS washes (3), the cells were
incubated with complete media supplemented with CellEvent
Caspase-3/7 Detection Reagent (5 mM) and DBCO-
p(DMAEMA)100/150 (0–125 mg mL
1). Images were taken at 0.5, 1,
2.5 and 4 h time intervals with a phase contrast channel and
a blue excitation laser. Ac4ManNAz untreated and treated cells
were also incubated with CellEvent Caspase-3/7 Detection
Reagent (5 mM) as control viable cells. Cells were counted using
ImageJ and values were reported as percentage caspase positive
cells relative to the total number of cells. Four biological repeats
were completed.
Fluorescent chemotherapeutic polymer and membrane stain
imaging
Ac4ManNAz treated and untreated A549 and SW480 cells (5k
cells) were seeded in CELLview™ Culture dishes in the presence
and absence of Ac4ManNAz (40 mM) and allowed to attach for
24 h. Cells were washed with DPBS (3) and subsequently© 2021 The Author(s). Published by the Royal Society of Chemistryincubated with DBCO-p(DMAEMA)100/150–Fl for 2.5 h. Polymer
solutions were removed and replaced with Leibovitz's L-15
Medium with no phenol red, following 3 DPBS washes. Z-
stack confocal imaging was completed immediately aer-
wards with a 63 objective lens, 488 nm excitation laser and
emission lters set to 493–634 nm; see ESI† for complete
confocal parameters. Cells were also imaged following treat-
ment with DBCO-p(DMAEMA)100/150 (2.5 h) and staining with
CellMask™ Deep Red Plasma membrane Stain (25 mg mL1,
100 mL, 30 min, RT) and NucBlue® Live Cell ReadyProbes®
Reagent (5 min at RT) in L15 media with no phenol red, with
DPBS washes (3) between steps. Z-stack confocal imaging was
completed with a 63 objective lens, 405 nm and 633 nm
excitation laser and emission lters set to 410–483 nm and 638–
747 nm. Maximum intensity projection images and 3D recon-
structions were produced using Zen 2.3.
Spheroid formation and metabolic oligosaccharide
engineering
MOE of A549 spheroids was achieved using 2 approaches, (1)
formation in Ac4ManNAz and (2) Ac4ManNAz treatment of pre-
formed spheroids. For approach (1), A549 cells were seeded (2k
cells per well) in an ultralow attachment U-bottom plate in the
presence and absence of Ac4ManNAz (40 mM) supplemented F-
12K complete media. The plate was centrifuged at 2k RPM for
10 min and spheroids were allowed to grow for 96 h in
a humidied atmosphere of 95% air and 5% CO2 at 37 C. For
approach (2), A549 cells were seeded (1k cells per well) in an
ultralow attachment U-bottom plate, in F-12K complete media,
centrifuged at 2k RPM for 10 min and allowed to grow for 72 h.
Following 72 h, the media was replaced with either complete
fresh media (no Ac4ManNAz) or complete fresh media supple-
mented with Ac4ManNAz (40 mM) and incubated for another
96 h in a humidied atmosphere.
Spheroid polymer treatment and viability assay
Azido glycan labelled and unlabelled spheroids, using both
approaches described above, were incubated with either DBCO-
p(DMAEMA)100/150 (0–500 mg mL
1, 100 mL) for 3 h or doxoru-
bicin (0–500 mg mL1, 100 mL) for 24 h. Following DPBS washes
(3), the chemotherapeutic solutions were replaced with fresh
media and an equal volume of CellTiter-Glo® (100 mL) was
subsequently added. The U-bottom plate was placed on a plate
shaker for 10 min to ensure lysis and allowed to equilibrate for
25 min at RT. The resulting solutions were transferred into an
opaque white plate to record luminescence measurements. Six
biological repeats were completed.
Spheroid cytoxicity imaging
Spheroids formed in the presence and absence of Ac4ManNAz
(approach (1) above) were incubated with DBCO-
p(DMAEMA)100/150 (31.3, 62.5 and 250 mg mL
1) for 3 h.
Following DPBS washes (3), the polymer solutions were
replaced with fresh media and an equal volume of CellTox™
Green reagent (100 mL, 2 concentration) for 15 min at RT.
Spheroids were centrifuged at 2k RPM for 5 min and Z-stackChem. Sci.
























































































View Article Onlineconfocal imaging was completed using a 10 objective lens,
a 488 nm excitation laser and emission lters set to 493–
634 nm. Spheroids untreated and treated with Ac4ManNAz, but
untreated with chemotherapeutic polymer solutions, were also
stained with CellTox™ Green reagent as negative controls and
lysis controls were prepared as positive controls; see ESI.†
Maximum intensity projection images and 3D reconstructions
were produced using Zen 2.3. Note: dead cells were converted
from green to red.Conflicts of interest
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